Nuhey News

We talk about the MARKET

3.3% CAGR to take Global Antiviral Drugs Market to USD 51390 Mn by 2028

Antiviral drugs are medicines that decrease the ability of flu viruses to reproduce. when used as directed, antiviral drugs may help reduce the duration of flu.

Due to the COVID-19 pandemic, the global Antiviral Drugs market size is estimated to be worth US$ 40870 million in 2021 and is forecast to a readjusted size of US$ 51390 million by 2028 with a CAGR of 3.3% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Antiviral Drugs market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Antiviral Drugs landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

In this market study, analysts have estimated the reverse transcriptase inhibitors to dominate the antiviral drugs market during the forecast period. These are compounds that are used to inhibit the reverse transcriptase enzyme.

The capability of this enzyme to catalyze the process of conversion of viral RNA into DNA, to infect the healthy host cell and replicate it is the key contributor to the growth of this segment in the hiv treatment drugs market.

This report focuses on Antiviral Drugs volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Antiviral Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.

Request for a free sample or purchase this report at:

The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type

  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Fusion Inhibitors
  • Immune System Modulators

Segment by Application

  • Hepatitis Therapeutics
  • HIV/AIDS Therapeutics
  • Herpes Therapeutics
  • Influenza Therapeutics

By Company

  • Roche
  • Johnson & Johnson
  • Merck
  • Novartis
  • Bristol-Myers Squibb
  • Gilead Sciences
  • GlaxoSmithKline
  • AbbVie

Production by Region

  • North America
  • Europe
  • China

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)


Contact Details:

Mr. Shirish Gupta

Sales Manager

The Market Reports | Industry and Market Reports at its Best

Call: +1-631-407-1315 / +91-750-729-1479